Physician profile
Ayham R Skaf
NPI 1285888628
$131,280.20
in general payments reported to CMS, 2019-2025
38 companies · $15K in 2025
The $15K reported for 2025 was more than what 93% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $12K · 2021: $10K · 2022: $18K · 2023: $21K · 2024: $17K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $10K · Consulting Fee: $4,475 · Honoraria: $3,975 · Travel and Lodging: $2,273 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,450.00 |
| Food and Beverage | $10,209.44 |
| Consulting Fee | $4,475.00 |
| Honoraria | $3,975.00 |
| Travel and Lodging | $2,272.94 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $52,726.30 | 2019-2025 | Ozurdex, Vuity, Alphagan P |
| Novartis Pharmaceuticals Corporation | $23,177.28 | 2019-2023 | |
| Allergan, INC. | $19,567.57 | 2019-2022 | |
| Alimera Sciences, INC. | $12,915.27 | 2019-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $7,676.25 | 2019-2025 | Clareon, Argos, Hydrus Microstent |
| Eyepoint US, INC. | $2,053.90 | 2019-2022 | |
| Glaukos Corporation | $2,026.16 | 2019-2024 | Idose |
| Regeneron Pharmaceuticals, INC. | $1,375.00 | 2023 | Eylea |
| Kala Pharmaceuticals, INC. | $1,347.28 | 2019-2022 | |
| New World Medical,INC. | $1,040.16 | 2021-2023 | |
| Biotissue Holdings INC. | $842.74 | 2019-2025 | |
| Genentech USA, INC. | $789.93 | 2021-2025 | Vabysmo, Susvimo, Lucentis |
| Mallinckrodt Hospital Products INC. | $655.88 | 2020-2025 | Acthar |
| Oyster Point Pharma, INC. | $649.79 | 2022-2025 | Tyrvaya, Ryzumvi |
| Apellis Pharmaceuticals, INC. | $601.64 | 2023-2025 | Syfovre |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $540.66 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $485.29 | 2022-2025 | Miebo, Stellaris, Xiidra |
| Astellas Pharma US INC | $429.04 | 2023-2025 | Izervay |
| Ivantis, INC | $359.51 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $339.52 | 2019-2021 | |
| Sight Sciences, INC. | $299.97 | 2022-2024 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $254.74 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $175.38 | 2024-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Regeneron Healthcare Solutions, INC. | $169.80 | 2019-2025 | Eylea Hd |
| Dompe US, INC. | $138.61 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $137.60 | 2021-2023 | Tepezza |
| Coherus Oncology, INC. | $125.00 | 2023 | |
| Biotronik INC. | $69.44 | 2022 | |
| Sun Pharmaceutical Industries INC. | $68.24 | 2019-2025 | Cequa |
| Thea Pharma INC. | $49.58 | 2022-2025 | Iyuzeh |
| Optos, INC. | $39.68 | 2021 | |
| Harrow Eye, LLC | $34.91 | 2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $28.46 | 2019 | |
| Shire North American Group INC | $22.19 | 2019 | |
| Merck Sharp & Dohme LLC | $19.15 | 2019 | |
| Dutch Ophthalmic, USA | $19.03 | 2022 | |
| Astellas Pharma Global Development | $15.34 | 2025 | Izervay |
| Rxsight INC | $13.91 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Handpiece |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayham Skaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.